Groowe Groowe / Newsroom / RNAC
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

RNAC News

Cartesian Therapeutics, Inc. Common Stock

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

globenewswire.com
RNAC

Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

globenewswire.com
RNAC

Cartesian Therapeutics Announces New Employment Inducement Grants

globenewswire.com
RNAC

Form 8-K

sec.gov
RNAC

Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

globenewswire.com
RNAC

Cartesian Therapeutics Announces New Employment Inducement Grants

globenewswire.com
RNAC

Form 8-K

sec.gov
RNAC

Form 8-K

sec.gov
RNAC

Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update

globenewswire.com
RNAC

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

globenewswire.com
RNAC